Literature DB >> 30192713

Dysbiosis signatures of gut microbiota in coronary artery disease.

Qi Zhu1,2, Renyuan Gao1,2, Yi Zhang3, Dengdeng Pan1,2, Yefei Zhu1,2, Xiaohui Zhang1,2, Rong Yang4, Rong Jiang3, Yawei Xu3, Huanlong Qin1,2.   

Abstract

Gut microbiota dysbiosis has been considered to be an important risk factor that contributes to coronary artery disease (CAD), but limited evidence exists about the involvement of gut microbiota in the disease. Our study aimed to characterize the dysbiosis signatures of gut microbiota in coronary artery disease. The gut microbiota represented in stool samples were collected from 70 patients with coronary artery disease and 98 healthy controls. 16S rRNA sequencing was applied, and bioinformatics methods were used to decipher taxon signatures and function alteration, as well as the microbial network and diagnostic model of gut microbiota in coronary artery disease. Gut microbiota showed decreased diversity and richness in patients with coronary artery disease. The composition of the microbial community changed; Escherichia-Shigella [false discovery rate (FDR = 7.5*10-5] and Enterococcus (FDR = 2.08*10-7) were significant enriched, while Faecalibacterium (FDR = 6.19*10-10), Subdoligranulum (FDR = 1.63*10-6), Roseburia (FDR = 1.95*10-9), and Eubacterium rectale (FDR = 2.35*10-4) were significant depleted in the CAD group. Consistent with the taxon changes, functions such as amino acid metabolism, phosphotransferase system, propanoate metabolism, lipopolysaccharide biosynthesis, and protein and tryptophan metabolism were found to be enhanced in CAD patients. The microbial network revealed that Faecalibacterium and Escherichia-Shigella were the microbiotas that dominated in the healthy control and CAD groups, respectively. The microbial diagnostic model based on random forest also showed probability in identifying those who suffered from CAD. Our study successfully identifies the dysbiosis signature, dysfunctions, and comprehensive networks of gut microbiota in CAD patients. Thus, modulation targeting the gut microbiota may be a novel strategy for CAD treatment.

Entities:  

Keywords:  coronary artery disease; diagnostic model; dysbiosis signatures; function alteration; microbial network

Mesh:

Substances:

Year:  2018        PMID: 30192713     DOI: 10.1152/physiolgenomics.00070.2018

Source DB:  PubMed          Journal:  Physiol Genomics        ISSN: 1094-8341            Impact factor:   3.107


  39 in total

Review 1.  [Gut-heart axis : How gut bacteria influence cardiovascular diseases].

Authors:  Hendrik Bartolomaeus; Victoria McParland; Nicola Wilck
Journal:  Herz       Date:  2020-04       Impact factor: 1.443

Review 2.  Host-microbial interactions in metabolic diseases: from diet to immunity.

Authors:  Ju-Hyung Lee; Joo-Hong Park
Journal:  J Microbiol       Date:  2022-05-05       Impact factor: 3.422

3.  Sleep and Circadian Disruption and the Gut Microbiome-Possible Links to Dysregulated Metabolism.

Authors:  Dana Withrow; Samuel J Bowers; Christopher M Depner; Antonio González; Amy C Reynolds; Kenneth P Wright
Journal:  Curr Opin Endocr Metab Res       Date:  2020-11-28

4.  Sleep and the gut microbiome in psoriasis: clinical implications for disease progression and the development of cardiometabolic comorbidities.

Authors:  Bridget Myers; Reddy Vidhatha; Brownstone Nicholas; Chan Stephanie; Thibodeaux Quinn; Hsin-Wen Chang; Tina Bhutani; Wilson Liao
Journal:  J Psoriasis Psoriatic Arthritis       Date:  2020-10-13

Review 5.  The potential of tailoring the gut microbiome to prevent and treat cardiometabolic disease.

Authors:  Rima Mohsen Chakaroun; Lisa M Olsson; Fredrik Bäckhed
Journal:  Nat Rev Cardiol       Date:  2022-10-14       Impact factor: 49.421

Review 6.  The role of the gut microbiota in health and cardiovascular diseases.

Authors:  Lu Wang; Shiqi Wang; Qing Zhang; Chengqi He; Chenying Fu; Quan Wei
Journal:  Mol Biomed       Date:  2022-10-11

7.  Gut Microbiota, Plasma Metabolomic Profiles, and Carotid Artery Atherosclerosis in HIV Infection.

Authors:  Zheng Wang; Brandilyn A Peters; Mykhaylo Usyk; Jiaqian Xing; David B Hanna; Tao Wang; Wendy S Post; Alan L Landay; Howard N Hodis; Kathleen Weber; Audrey French; Elizabeth T Golub; Jason Lazar; Deborah Gustafson; Seble Kassaye; Bradley Aouizerat; Sabina Haberlen; Carlos Malvestutto; Matthew Budoff; Steven M Wolinsky; Anjali Sharma; Kathryn Anastos; Clary B Clish; Robert C Kaplan; Robert D Burk; Qibin Qi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2022-06-09       Impact factor: 10.514

8.  Ten-year changes in plasma L-carnitine levels and risk of coronary heart disease.

Authors:  Yoriko Heianza; Wenjie Ma; Joseph A DiDonato; Qi Sun; Eric B Rimm; Frank B Hu; Kathryn M Rexrode; JoAnn E Manson; Lu Qi
Journal:  Eur J Nutr       Date:  2021-11-19       Impact factor: 4.865

Review 9.  Could Artificial Intelligence/Machine Learning and Inclusion of Diet-Gut Microbiome Interactions Improve Disease Risk Prediction? Case Study: Coronary Artery Disease.

Authors:  Baiba Vilne; Juris Ķibilds; Inese Siksna; Ilva Lazda; Olga Valciņa; Angelika Krūmiņa
Journal:  Front Microbiol       Date:  2022-04-11       Impact factor: 6.064

10.  Bifidobacterium lactis Probio-M8 Adjuvant Treatment Confers Added Benefits to Patients with Coronary Artery Disease via Target Modulation of the Gut-Heart/-Brain Axes.

Authors:  Baoqing Sun; Teng Ma; Yalin Li; Ni Yang; Bohai Li; Xinfu Zhou; Shuai Guo; Shukun Zhang; Lai-Yu Kwok; Zhihong Sun; Heping Zhang
Journal:  mSystems       Date:  2022-03-28       Impact factor: 7.324

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.